Abstract: A pet identification tag with associated cavity holder for insertion of a miniaturized Radio-frequency identification (“RFID”) transponder capsule. The tag has an embedded cavity and mechanism to insert or remove an optional RFID transponder capsule. The tag with transponder capsule can then be attached to a pet's collar to wireless ID the pet without need to medically inject a RFID transponder capsule into a pet's body by surgical means.

Abstract: The present invention is a system and method for identifying and returning an object includes affixing to the object a passive two-way communication circuit such as a frangible radio security tag or smart label. The tag or label, when operational, is arranged to receive a remotely generated request for status information and, responsive to the request, to transmit status information to a remote device. If desired, the radio tag can be incorporated into a printed label, each label having an adhesive side and a printable side with information to notify the ‘finder’ of a tagged item to coordinate return to its registered owner by contacting a courier, postal or other delivery service network. In the event that a tagged item should become misplaced, the carrier and the supplier can cooperate to locate it and inform the owner of its whereabouts by using the information provided upon enrollment to an electronic ‘lost and found’ network service.

Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.